ClinicalTrials.gg
CompletedNCT05565820Updated Feb 24, 2025Results posted

A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation

A Phase 4 interventional study of Vamousse Spray 'n' Go and Nix Creme Rinse Lice Treatment in Pediculosis Capitis, Lice Infestations and Head Lice, sponsored by Alliance Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 2 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Alliance Pharmaceuticals · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
2 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of Vamousse Spray 'n' Go, compared to a 1% Permethrin control shampoo, in the treatment of head lice.

Read the detailed description

This is a Study to Evaluate the Safety and Efficacy of Alliance Pharmaceutical Product in Subjects Infested with Pediculosis Capitis. The subject population includes healthy male and female subjects aged 2 years and up who are infested with Pediculus humanus capitis. Household members infestation with an active head lice, defined as at least 1 live louse (adult and/or nymph) present on the scalp and/or hair as determined by a trained evaluator, will receive treatment with study product at baseline.

The planned overall sample size for this clinical trial is approximately n=58 subjects, equally divided between treatment and control groups. Potential subjects will be screened for eligibility and if eligible to participate, their infestation level will be rated. Eligible subjects at each infestation level will be assigned alternately to the treatment or control group to ensure that the two groups have approximately equal representations of infestation severity levels. Level of infestation will be rated as heavy, moderate or light described by how quickly lice were found during combing: heavy infestation = >1 louse with one stroke of the comb; moderate infestation =1 louse with one stroke of the comb; light infestation = first louse found only after several strokes of the comb.

Randomly assign subjects to treatment or control group based on infestation severity alternation system (i.e., randomly assign pairs of equal severity levels to treatment and control groups, a form of stratified random sampling) to achieve balanced representation of severity in the two groups.

After assignment to a study group, each eligible subject will receive the application of either the Alliance Pharmaceutical Product Vamousse Spray 'n' Go drug or the Permethrin-based control drug. Infested household members will be treated with the Vamousse Spray 'n' Go or Permethrin lotion on-site (i.e., the household members should be assigned to the same treatment as the index case). During the baseline visit (Day 0), the Investigator and clinical staff members will record subject's demographics; elicit informed consent; obtain medical history; review concomitant medication to identify any prohibited therapies the subject may be receiving; collect vital signs; conduct visual assessment of head lice, specifically counting live lice and nits with stages noted, using a 15 inch led 5x magnifying procedure lamp and if needed for confirmation, laboratory microscopes; perform physical examination; assess local skin/ scalp irritation; assess ocular irritation; perform urine pregnancy test on females; and conduct an adverse event assessment.

At day 7, if live lice are still present, a repeat treatment will be administered. After day 7 if a subject reports clear signs of infestation ( i.e., the presence of live lice), they will be regarded as a treatment failure and they will be offered treatment with an alternative product (viz., Vamousse Mousse ) by clinical staff.

For the treatment group, Clinical staff will apply Vamousse Spray 'n' Go to fully coat dry hair and scalp, avoiding the eyes and mucus membranes. The Treatment will be left on the hair and scalp for 8 hours, then standard at home shampoo and rinsed off with warm water, followed by combing. The Treatment spray bottle is intended for a single use although it contains a sufficient quantity for two treatments. All household members will be instructed on an overall lice management program, which includes:

  • Wash (in hot water) or dry-clean all recently worn clothing, hats, used bedding and towels.
  • Wash (in hot water) personal care items such as combs, brushes and hair clips.
  • Record time and date product shampoo/rinse 8 hours post treatment

For the control group, Clinical staff will first shampoo the hair and scalp using regular shampoo. They will then thoroughly rinse and towel dry the hair and scalp, and allow hair to air dry for a few minutes. Shaking the permethrin lotion well before applying, they will proceed to thoroughly wet the hair and scalp with the permethrin lotion, being sure also to cover the areas behind the ears and on the back of the neck. After allowing the lotion to remain in place for 10 minutes, they will then rinse the hair and scalp thoroughly and dry with a clean towel.

The site will provide Subject with lice management instructions. Subjects will return for post-baseline visits assessments at Day 2, Day 7, and Day 14.

Day 2: The Investigator and medical staff will collect medical history, collect vital signs, perform physical examination, scalp irritation assessment, ocular irritation assessment and adverse events assessment, perform a visual assessment for the presence or absence of head lice, (Lice will be counted, each stage examined and noted live or dead; 15in led 5x magnifying procedure lamp or laboratory microscopes are used for confirmation if needed, Without clipping hair strands, nits will also be examined, each stage examined and noted hatched or unhatched), and adverse events assessment Urine pregnancy testing will be performed on each Visit, with interim visits confirming pregnancy has not occurred through questioning participating subject and legal guardian.

Day 7: The Investigator and medical staff will collect medical history, collect vital signs, perform a physical examination, assess scalp irritation, assess ocular irritation and adverse events, perform a visual assessment for the presence of head lice (lice will be counted, each stage identified, and noted live or dead; 15in led 5x magnifying procedure lamp or laboratory microscopes will be used for confirmation if needed; without clipping hair strands, nits will also be examined, each stage examined, and noted hatched or unhatched). Urine pregnancy testing of females will be performed on each visit, with interim visits confirming pregnancy has not occurred through questioning participating subject and legal guardian. If, at day 7, live lice are still present, a repeat Vamousse Spray 'n' Go or Permethrin (depending on study group) shampoo treatment will be administered.

Day 14: The Investigator and medical staff will collect medical history, concomitant and prohibited medication review, perform vital signs, urine pregnancy testing if applicable, perform physical examination, record local application site reactions, ocular irritation assessment, perform a visual assessment for the presence of head lice (lice will be removed, counted, each stage examined and noted live or dead; 15 inch led 5x magnifying procedure lamp or laboratory microscopes are used for confirmation; nits will also be removed by clipping hair strands, examined, each stage counted, and noted as hatched or unhatched) and adverse events assessment. By day 14 if a subject reports clear signs of infestation (i.e., the presence of live lice) they will be regarded as a treatment failure and will be offered treatment with an alternative product (Vamousse Mousse) by clinical staff.

02

Conditions studied

  • Pediculosis Capitis
  • Lice Infestations
  • Head Lice

Keywords

  • Phthiraptera
  • Pediculus humanus Capitis
  • Pediculidae
  • Parasitic Diseases
  • Human Head Louse
  • Pediculi
  • Nits
  • Homeopathy
  • Homeopathic Pharmacopoeias
  • Homeopathic Formularies
  • Insecticides
  • Parasitology
03

In context

Lice Infestations

43 studies on the registry are indexed under Lice Infestations; 4 are open to participants now.

This study's enrollment of 58 is below the median of 105 across 42 interventional studies indexed under Lice Infestations.

Browse Lice Infestations studies →

Lead sponsor

This is the only study on the registry with Alliance Pharmaceuticals as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have an active head lice infestation defined as: at least 1 live lice (adults and/or nymphs) present on the scalp and/or hair, as determined by a trained evaluator.
  • Subjects must be at least two (2) years of age through 75 years of age, presenting with an active head lice infestation.
  • Subject is male or female.
  • Subject is in good general health based on medical history.
  • Each subject must have an appropriately signed agreement. A caregiver must sign an Informed Consent agreement for children not old enough to do so. Children 6-17 years of age will be administered a child's Assent Form.
  • The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, they must be willing and able to participate in receiving study product or Standard of Care.
  • Subject agrees not to use any other form of lice treatments (commercial, community-anecdotal, or mechanical/manual) while participating in the study.
  • Following application of the test product, subject agrees not to shampoo, wash or rinse their hair or scalp until 8-hour post-treatment time has been reached and documented.
  • Subject agrees not to cut or chemically treat their hair while participating in the study.
  • Subject agrees to follow all study instructions, including attending all follow-up appointments.
  • Female subjects of must be willing to have a urine pregnancy test prior to inclusion in this study.

Exclusion criteria

Exclusion Criteria:

  • History of irritation or sensitivity to Nature Muriaticum 2X (HPUS) or Vamousse Spray 'n' Go or the components, pediculicides or hair care products.
  • Presentation at the treatment site with visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score and atopic dermatitis that is >2, blisters, vesicles which, in the opinion of the investigative personnel or medical monitor, will interfere with safety and/or efficacy evaluations.
  • Presentation at the treatment site with eczema or atopic dermatitis.
  • Treatment for head lice (Over the Counter, home remedy and/or Prescription) in the last 30 days.
  • Any condition or illness that, in the opinion of the investigator, may compromise the objective of the protocol.
  • Subject is receiving any other treatment which, in the opinion of the investigator or medical monitor, may interfere with the study results.
  • Females (including caregivers who come in contact with the product) who are pregnant, nursing or planning a pregnancy which could include household subjects. If a household has a pregnant female who has an active case of lice, the entire household is excluded from participation and provided Standard of Care.
  • Household members of , including subjects, and unwilling to use an adequate method of for the duration of the study. Adequate methods of contraception include: abstinence, vasectomised partner, oral birth control pills, birth control injections or patches, intra uterine devices, condoms with a spermicidal jelly or a diaphragm with spermicidal jelly, surgical sterilisation. Subjects and/or caregivers will be considered non-child-bearing if the following has occurred: full hysterectomy or bilateral oophorectomy is considered surgically sterile. Tubal ligation is not considered equivalent to female sterilisation.
  • Participation in a previous investigational drug study within the past 30 days.
  • Does not understand the requirements for study participation and/or may likely exhibit poor compliance, in the opinion of the investigator.
  • Does not have a known household affiliation with their household members (i.e., do not stay in one household consistently, sleeping at one place several nights and then at another place or location). Household is defined as living in a shared area or space (for example the same house of apartment unit).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Vamousse Spray 'n' Go

    Clinical staff will apply Vamousse Spray 'n' Go during the baseline visit (Day 0) to fully coat the hair and scalp. The treatment will be left on for 8 hours, then standard at home shampoo will be used and rinsed off with warm water, followed by combing. At day 7, if live lice are still present, a repeat treatment will be administered.

    Other: Vamousse Spray 'n' Go

  • Active comparator
    Nix Creme Rinse Lice Treatment

    During the baseline visit (Day 0) clinical staff will first shampoo the hair and scalp using regular shampoo. They will then thoroughly rinse and towel dry the hair and scalp, and allow hair to air dry for a few minutes. Staff will shake Nix Creme Rinse Lice Treatment (1% permethrin lotion) well before applying, they will then proceed to thoroughly wet the hair and scalp with the lotion, being sure to cover the areas behind the ears and on the back of the neck. After allowing the lotion to remain in place for 10 minutes, they will rinse the hair and scalp thoroughly and dry with a clean towel. At day 7, if live lice are still present, a repeat treatment will be administered.

    Drug: Nix Creme Rinse Lice Treatment

Interventions

  • OtherVamousse Spray 'n' Go

    Pediculicide for topical application, active ingredient Natrum Muriaticum 2X (HPUS).

  • DrugNix Creme Rinse Lice Treatment

    1% permethrin lotion for topical application.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Who Are Completely Free of Live Lice

    The total numbers of subjects in each group free of live lice at Days 2, 7, and 14, where 'live lice free" is defined as no presence of live adult or nymph lice. Zero subjects in each group were free of live lice at baseline. Since the two groups differed substantially in size, the numbers of live lice free subjects in each group at Days 2, 7, and 14 were transformed for analytical purposes to proportions of the respective group's participant totals on the respective days in order to achieve a metric that reflects commensurate degrees of difference between the two groups.

    Time frame: 2, 7, and 14 days from baseline

Secondary outcomes

  1. Proportion of Change in Total Number of Live Adult Lice and Nymphs From the Baseline

    The counts of live lice at Days 2, 7, and 14 for were subtracted from the respective each participant's baseline count for the respective day. The resulting raw differences were transformed for analytical purposes to proportions of the respective participant's baseline live lice count in order to achieve a metric that reflected commensurate degrees of change, the means of which could be compared between the two groups for each interval from baseline. All proportions of change from baseline are negatively signed to reflect a reduction in the count from baseline, which occurred for both groups on all 3 post-baseline assessment days.

    Time frame: 2, 7, and 14 days from baseline

07

Results

Posted Feb 24, 2025

Participant flow

2 Day Treatment Effectiveness
Participant flow — 2 Day Treatment Effectiveness
MilestoneVamousse Spray 'n' GoNix Creme Rinse Lice Treatment
Started4315
Completed4315
Not completed00
7 Day Treatment Effectiveness
Participant flow — 7 Day Treatment Effectiveness
MilestoneVamousse Spray 'n' GoNix Creme Rinse Lice Treatment
Started4315
Completed4115
Not completed20
Withdrew: Withdrawal by subject20
14 Day Treatment Effectiveness
Participant flow — 14 Day Treatment Effectiveness
MilestoneVamousse Spray 'n' GoNix Creme Rinse Lice Treatment
Started4315
Completed4115
Not completed20
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryProportion of Participants Who Are Completely Free of Live Lice

The total numbers of subjects in each group free of live lice at Days 2, 7, and 14, where 'live lice free" is defined as no presence of live adult or nymph lice. Zero subjects in each group were free of live lice at baseline. Since the two groups differed substantially in size, the numbers of live lice free subjects in each group at Days 2, 7, and 14 were transformed for analytical purposes to proportions of the respective group's participant totals on the respective days in order to achieve a metric that reflects commensurate degrees of difference between the two groups.

Time frame:
2, 7, and 14 days from baseline
Reported as:
Number · proportion of subjects free of live lice
Proportion of Participants Who Are Completely Free of Live Lice
proportion of subjects free of live liceVamousse Spray 'n' GoNix Creme Rinse Lice Treatment
Baseline proportion0.000.00
Day 2 proportion.535.200
Day 7 proportion.415.067
Day 14 proportion.683.400
Statistical analysis
  • Vamousse Spray 'n' Go vs Nix Creme Rinse Lice Treatment · Z-test for difference in proportions · p = .025 (Alpha: .05) · Difference in proportions: -.335Direction of comparison: Vamousse Day 2 proportion of live lice - Nix Day 2 proportion of live lice
  • Vamousse Spray 'n' Go vs Nix Creme Rinse Lice Treatment · Z-test for difference in proportions · p = .014 (Alpha: .05.) · Difference in proportions: .348Direction of comparison: Vamousse Day 7 proportion live lice free - Nix Day 7 proportion live lice free
  • Vamousse Spray 'n' Go vs Nix Creme Rinse Lice Treatment · Z-test for difference in proportions · p = .054 (Alpha: .05) · Difference in proportions: .283Vamousse Day 14 proportion live lice free - Nix Day 14 proportion live lice free
SecondaryProportion of Change in Total Number of Live Adult Lice and Nymphs From the Baseline

The counts of live lice at Days 2, 7, and 14 for were subtracted from the respective each participant's baseline count for the respective day. The resulting raw differences were transformed for analytical purposes to proportions of the respective participant's baseline live lice count in order to achieve a metric that reflected commensurate degrees of change, the means of which could be compared between the two groups for each interval from baseline. All proportions of change from baseline are negatively signed to reflect a reduction in the count from baseline, which occurred for both groups on all 3 post-baseline assessment days.

Time frame:
2, 7, and 14 days from baseline
Reported as:
Mean · proportion of change in number live lice
Proportion of Change in Total Number of Live Adult Lice and Nymphs From the Baseline
proportion of change in number live liceVamousse Spray 'n' GoNix Creme Rinse Lice Treatment
Day 2 proportion of change from baseline-.859 ± .225-.564 ± .424
Day 7 proportion of change from baseline-.762 ± .666-.549 ± .370
Day 14 proportion of change from baseline-.926 ± .177-.691 ± .386
Statistical analysis
  • Vamousse Spray 'n' Go vs Nix Creme Rinse Lice Treatment · t-test, 2 sided · p = .020 (Alpha = .05 t: 2.567 df (adjusted, see comment below): 16.83 Mann-Whitney Z: 2.830 p(2-tailed) of Mann-Whitney Z: .005 Cohen's d = 1.023) · Mean difference (final values): .295 · 95% CI .052 to .537Direction of comparison: Vamousse prop. reduction in live lice count from Day O - Nix prop. reduction in live lice count from Day O
  • Vamousse Spray 'n' Go vs Nix Creme Rinse Lice Treatment · t-test, 2 sided · p = .334 (Alpha = .05 t: .976 df: 54 Mann-Whitney Z: 3.021 p(2-tailed) of Mann-Whitney Z: .003 Cohen's d = .294) · Mean difference (final values): .178 · 95% CI -.187 to .543Levine's test for violation of equality of variances nonsignificant; no df adjustment necessary.
  • Vamousse Spray 'n' Go vs Nix Creme Rinse Lice Treatment · t-test, 2 sided · p = .037 (Alpha = .05 t: 2.276 df(adjusted, see comment below): 16.2 Mann-Whitney Z: 2.478 p(2-tailed) of Mann-Whitney Z: .013 Cohen's d = .947) · Difference between proportions: .235 · 95% CI .016 to .454Degrees of freedom for the t-test were adjusted for inequality of variances between the groups using the Satterthwaite correction: df(adj) = 16.2

Adverse events

Collected over Day 0 through Day 14 for each participant.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vamousse Spray 'n' Go0/43 (0%)0/43 (0%)0/43 (0%)
Nix Creme Rinse Lice Treatment0/15 (0%)0/15 (0%)0/15 (0%)

Baseline characteristics

The pattern of infestation levels of the primary participant in each household and the sizes of the households that were encountered in the sequential enrollment process resulted in an imbalance between the numbers of participants in the two treatment groups by the time that the study total of 58 participants was reached. Resources did not permit further enlargement of the sample to reduce this imbalance, but the power of the study to detect the difference that occurred remained high at .95.

Age, Categorical
Age, Categorical(Participants)Vamousse Spray 'n' GoNix Creme Rinse Lice TreatmentTotal
<=18 years281240
Between 18 and 65 years15318
>=65 years000
Age, Continuous
Age, Continuous(years)Vamousse Spray 'n' GoNix Creme Rinse Lice TreatmentTotal
Mean18.72 ± 14.2713.93 ± 13.8717.48 ± 14.32
Sex: Female, Male
Sex: Female, Male(Participants)Vamousse Spray 'n' GoNix Creme Rinse Lice TreatmentTotal
Female391453
Male415
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vamousse Spray 'n' GoNix Creme Rinse Lice TreatmentTotal
White/Hispanic431558
Region of Enrollment
Region of Enrollment(Participants)Vamousse Spray 'n' GoNix Creme Rinse Lice TreatmentTotal
United States431558
Count of live lice
Count of live lice(live lice)Vamousse Spray 'n' GoNix Creme Rinse Lice TreatmentTotal
Number12702881558
08

Study locations

1 site
  • South Florida Family Health and Research Centers, LLC.
    Miami, Florida 33186, United States
09

References and documents

Publications

  • Barker SC, Burgess I, Meinking TL, Mumcuoglu KY. International guidelines for clinical trials with pediculicides. Int J Dermatol. 2012 Jul;51(7):853-8. doi: 10.1111/j.1365-4632.2011.05446.x. PubMed 22715834 ↗
  • Birkemoe T, Lindstedt HH, Ottesen P, Soleng A, Naess O, Rukke BA. Head lice predictors and infestation dynamics among primary school children in Norway. Fam Pract. 2016 Feb;33(1):23-9. doi: 10.1093/fampra/cmv081. Epub 2015 Oct 28. PubMed 26511728 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05565820
Lead sponsor
Alliance Pharmaceuticals
Collaborators
South Florida Family Health and Research Centers
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Dec 15, 2022
Primary completion
Mar 12, 2023
Completion
Mar 12, 2023
Results posted
Feb 24, 2025
Last update
Feb 24, 2025

Study contacts

Susel L Gonzalez Acosta, APRN
principal investigator · South Florida Family Health and Research Centers

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion